Alzheimer’s Disease Metabolomics Consortium

The Alzheimer’s Disease Metabolomics Consortium (ADMC), led by Dr. Rima Kaddurah-Daouk at Duke University Medical Center, brings together leaders in Alzheimer’s disease (AD) clinical and basic research to work in close collaboration with centers of excellence in metabolomics, genetics, biochemistry, engineering, and bioinformatics. We aim to define metabolic failures across the trajectory of disease connecting peripheral and central changes. We define alterations in biochemical pathways and networks that can help us gain deeper understanding of disease mechanisms and that can highlight novel targets for drug design. We are a part of NIA funded national initiatives that includes Accelerating Medicines Partnership of Alzheimer Disease (AMP-AD) and Molecular Mechanisms of Vascular Etiology of Alzheimer Disease (MOVE-AD).